Cerevel Therapeutics Holdings is a biopharmaceutical company that develops therapies for neuroscience diseases. Its products include emraclidine and Darigabat, positive allosteric modulators in clinical trials for schizophrenia, focal onset seizures in epilepsy, and acute anxiety. The company is also focused on developing treatments for Parkinson's, dementia-related apathy, substance use disorder, major depressive disorder, psychosis, and disease progression in Parkinson's.